TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TMT Fusion Plate vs. Two Crossed Screws

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: between 18 and 65 years~* At least one of the following:~  * 1st TMT arthritis~ * hallux valgus (intermetatarsal angle (IM) 1-2 angle \> 15° on plain x-ray)~ * 1st ray hypermobility with or without flat foot~* Painful condition~* Ability to understand the content of the patient information / Informed Consent Form~* Willingness and ability to participate in the clinical investigation according to the Clinical Investigation Plan (CIP)~* Signed and dated IRB/EC-approved written informed consent~Exclusion Criteria:~* Active infection~* Previous surgery on the 1st ray of the same foot~* Previous non-union on the 1st ray of the same foot~* Clinical obvious arthritis in other joints of the lower extremities~* Purely seeking plastic surgery~* Peripheral vascular disease (e.g. advanced diabetes)~* Peripheral sensory neuropathy (e.g. advanced diabetes)~* Concurrent surgery of the contralateral foot~* Any previously medically unmanaged severe systemic disease~* Substance abuse that would preclude reliable assessment~* Prisoner~* Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TMT Fusion Plate (Type: OTHER): Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
- Two crossed screws (Type: OTHER): Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a New Sequencing Strategy in Autoinflammatory Siseases (BIOSAID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with prerequisites established jointly by the reference centers:~* At least 3 unexplained inflammatory access~* Elevated C Reactive Protein~* Age of symtoms less than 30 years and validated by a physician CeréMAI (Centre de référence des maladies autoinflamatoires)~Exclusion Criteria:~* Other inflammatory disease:~* intercurrent infection~* cancer~* autoimmune disease

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blind Elderly Melatonin Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 55-100 years old~* Blindness for at least one year, verified by an ophthalmologic exam~* Ability to comply with the requirements of the experimental protocol~* No clinically significant abnormalities (other than blindness) on a general physical examination~* Subjects must be competent to sign informed consent~Exclusion Criteria:~* Abnormal heart, liver or kidney function; a current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual~* A diagnosis of obstructive sleep apnea (apnea index \> 10) or nocturnal myoclonus (\> 10 associated arousals/hour)~* External demands that limit the ability to maintain a regular schedule, e.g., night shift work

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
- 2 (Type: EXPERIMENTAL): Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
- 3 (Type: EXPERIMENTAL): Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
- 4 (Type: EXPERIMENTAL): Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Central Sleep Apnoea in Patients With Heart Failure With Nasal High Flow Therapy (nHFT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate to severe CSA/CSR (AHI\>15), in which CSA is defined when at least 50% of the apnoeas are central apnoeas~2. Heart failure with reduced ejection fraction, defined as a LVEF \< 45% of predicted~Exclusion Criteria:~1. Other diseases affecting respiration during sleep (COPD GOLD 3 or 4, neuromuscular disorders, thorax cage deformities)~2. At the moment of the inclusion, the patient does not have a therapy to treat the CSA, such as continuous positive airway pressure (CPAP), oxygen, bilevel intermittent positive airway pressure (BiPAP) or acetazolamide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasal high flow oxygen therapy (Type: EXPERIMENTAL): The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~* Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~* High flow rate: 40-50 L/min without additional oxygen~* Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~* High flow rate: 40-50 L/min with FiO2 of 28%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan in Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years and over and to be treated with Vincristine for non-Hodgkin B lymphoma (first line treatment)~* All the patients have to be treated with the same chemotherapy protocol (CHOP with or without Rituximab) to avoid confounding factors~* Normal renal function as measured by CKD-EPI \> 30 mmol / min / 1.73 m2~* Serum potassium \< 5.5 mmol / l~* Systolic arterial pressure \> 100 mm Hg (lying and standing position)~* affiliated with a social security~* For women of childbearing age: under highly effective contraception and negative pregnancy test at inclusion. Highly effective contraception:~  * Combined hormonal contraceptive (containing estrogen and progesterone) (oral, intravaginal, or transdermal) or only progesterone (oral, injectable or implantable),~Exclusion Criteria:~* Patients with pre-existing neuropathy, Chronic ethylism, HIV infection, etc.~* Patients under guardianship or unable for another reason to give informed consent.~* Intolerance to sartans~* Intolerance to excipients : galactose , lactose.~* Patients already treated with ACE inhibitors, ARBs or/and diuretics sparing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Candesartan (Type: EXPERIMENTAL): None
- Usual care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Attention Training in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* They are above 18 years.~* They have had a stroke.~Exclusion Criteria:~* They or their legal representative are unable to provide informed consent.~* They have a severe comorbid psychiatric (E.g. psychotic symptoms) disorder.~* They have a premorbid neurodegenerative disease (E.g. Alzheimer's dementia, vascular dementia).~* They have severe written language comprehension deficits.~* They have a medical implant, such as a cochlear implant or a pacemaker.~* They have a severe visual or auditory impairment that cannot be corrected for by wearing glasses or a hearing aid while wearing the Oculus Rift headset.~* They are unable to concentrate on a task for more than 15 minutes or are unable to complete a task according to simple task instructions.~* They have a history of epileptic seizures.~* They do not show signs of a spatial asymmetry in performance on a battery of screening tasks.~* The expected discharge of patients is in a period shorter than 7 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
- Group B (Type: EXPERIMENTAL): In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form.~* Male or non-pregnant, non-lactating female, ≥ 18 years.~* Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk or arms.~* nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth.~* Willing and able to participate in the trial as an outpatient and comply with all trial requirements.~Exclusion Criteria:~* nBCC located close to or at mouth or eyes.~* Patients who have had an organ transplant.~* Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV), known thyroid abnormalities, known depression.~* An open wound or an infection in treatment area.~* Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the treatment or surrounding area that might impair trial assessments.~* Evidence of an active infection or systemic cancer.~* Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle pain, chills) within a week before start of the trial.~* Known allergy or hypersensitivity to any of the trial gel ingredients.~* Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., renal or hepatic disease).~* Current alcohol abuse or chemical dependency as assessed by the investigator.~* Patient who is detained or committed to an institution by a law court or by legal authorities.~* Participation in another clinical trial within one month before start of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.06% Resiquimod Gel - A (Type: EXPERIMENTAL): * 60 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
- 0.06% Resiquimod Gel - B (Type: EXPERIMENTAL): * 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
- 0.06% Resiquimod Gel - C (Type: EXPERIMENTAL): * 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~* The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Was either a P neonate born at least 27 weeks to less than 34 weeks of gestational age (GA) or a TNT neonate born at least 34 weeks but no more than 40 weeks of GA.~2. Was administered INOmax therapy after birth to 7 days of age via any route (invasive or noninvasive ventilation) for a minimum treatment period of at least 24 hours up to 96 ± 12 hours. The participants may receive INOmax for a longer period.~3. Had PH, as confirmed by echocardiogram or a differential saturation gradient of at least 10%.~4. Received INOmax administration as part of routine clinical practice in a Level III or higher neonatal intensive care unit in the United States.~5. Has all variables required to calculate OI or SOI (a baseline sample prior to treatment and 4 samples obtained during treatment).~Exclusion Criteria:~1. Was at risk of imminent death (death expected within 24 hours).~2. Received extracorporeal membrane oxygenation (ECMO).~3. Had a life-threatening abnormality (cranial, cardiac, thoracic), chromosomal abnormality, congenital diaphragmatic hernia, congenital heart defect (other than patent ductus arteriosus or small atrial septal defect).~4. Had been resuscitated requiring chest compressions within 6 hours of receiving INOmax.~5. Had Grade IV bilateral intraventricular hemorrhage or periventricular leukomalacia.~6. Had active uncontrolled bleeding.~7. Had disseminated intravascular coagulopathy.~8. Had active seizures while receiving anticonvulsants.~9. Experienced prolonged asphyxia with evidence of severe acidosis (pH \< 7.25).~10. Received concomitant pulmonary vasodilator therapy (eg, prostacyclin or sildenafil) except when sildenafil was used to wean the participant from INOmax therapy.

- Gender: ALL
- Minimum Age: 27 Weeks
- Maximum Age: 40 Weeks
- Healthy Volunteers: f

Study Arms:
- P Neonates (Type: None): Premature (P) neonates \[at least 27 weeks but less than 34 weeks of gestational age\]
- TNT Neonates (Type: None): Term-Near-Term (TNT) neonates at least 34 weeks of gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed of PCOS according to Rotterdam 2003 criteria~Exclusion Criteria:~* BMI \>30~* Pharmacological treatment in the last 3 moths~* Use of contraceptive pill

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Inositol (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have biopsy-confirmed non-Hodgkin lymphoma, of any type~* Must be eligible for autologous transplantation according to institutional guidelines~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Karnofsky performance status of 70 to 100~* Negative for human immunodeficiency virus (HIV)~* prior to the start of mobilization, subjects must have:~  * Absolute neutrophil count of \>= 1.2 x 10\^9/L~ * Platelet count of \>= 100 x 10\^9/L~ * Creatinine clearance \>= 30 mL/minute~* All patients must be able to comprehend and sign informed consent~* If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy~Exclusion Criteria:~* Have had previous transplants and/or prior mobilization attempts~* Have evidence of progressive non-Hodgkin lymphoma~* Have evidence of bone marrow involvement of lymphoma at time of transplant staging~* Had evidence of active central nervous system (CNS) involvement~* Have had previous radiation of the pelvic area~* Have had prior radioimmunotherapy~* Have received experimental therapy within 2 weeks of enrollment~* Be currently enrolled in another investigational protocol~* Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (stem cell supermobilization) (Type: EXPERIMENTAL): Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contrast Enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Cerebral Vasospasm After SAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Proven SAH (CT or lumbar puncture)~* Proven aneurysm (digital subtraction angiography or CT-angiography)~* Age \>18~* Informed consent of patient or relative~Exclusion Criteria:~* Pregnancy and breast feeding~* Acute coronary syndromes, severe ischemic heart disease (requiring revascularisation), severe aortic and mitral valve disease, severe congestive heart failure (NYHA \>III/IV)~* Severe pulmonary or renal dysfunction~* Known allergy or adverse reaction to contrast material

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound perfusion imaging (Type: None): Measuring methods of UPI with phase inversion harmonic imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues